Fol News

Tutti gli approfondimenti
Tutte le notizie

bmsn$rgbp$bnikf

  • Trading Day 19 aprile Torino - Corso Gratuito sull'investimento

    Migliora la tua strategia di trading con le preziose intuizioni dei nostri esperti su oro, materie prime, analisi tecnica, criptovalute e molto altro ancora. Iscriviti subito per partecipare gratuitamente allo Swissquote Trading Day.

    Per continuare a leggere visita questo LINK
adesso possiamo fare due conti
forse$$$$$$$$$$$$$$$$$$
cmq.
siamo aggiornati
è questo il bello!!!!!!!!!!!!!!!!!!!!!!!
mangeremo il panettone
con la sorpresa

c'è anche la conferma del nuovo presidente

il cerchio si chiudeeeeeeeeeeeeeeeeeeeeeeeee$$$$$$$$$$$$

cosi mi piace

gooooooooooooo
regen
 
Ma tutto st'entusiasmo cosa mi rappresenta?

cambiato spacciatore? :D:D
 
Ok finalmente un po' di liquidità mi ha permesso di prenderne un po' a 0,15 di Regen :D

In attesa che regen scenda a 0,10 dove spero di comprarne un altro po' :yes:,
la prossima settimana inizio a rastrellare BMSN a 0,0002...:cool:
Ho il presentimento che BMSN non è finita :censored:
1 billion return to treasury, % di partecipazione in Regen, another divy in Regen shares, tanti scenari insomma...è nebulosa per ora, però non credo sia finita qui per BMSN...:mmmm:

BMSN
Bio-Matrix Scientific Group Inc. (BMSN): 4.2B OS

proviamoci :clap:
 
Italia77 ha scritto:
Ok finalmente un po' di liquidità mi ha permesso di prenderne un po' a 0,15 di Regen :D

In attesa che regen scenda a 0,10 dove spero di comprarne un altro po' :yes:,
la prossima settimana inizio a rastrellare BMSN a 0,0002...:cool:
Ho il presentimento che BMSN non è finita :censored:
1 billion return to treasury, % di partecipazione in Regen, another divy in Regen shares, tanti scenari insomma...è nebulosa per ora, però non credo sia finita qui per BMSN...:mmmm:

BMSN
Bio-Matrix Scientific Group Inc. (BMSN): 4.2B OS

proviamoci :clap:
Clicca per espandere...
A/S 8B

provaci tu se vuoi...io :no:
 
hai preso qualcosa gabry$$$$$$$$$$$$$$$$$$$$$$$$4
 
June 10, 2015 /PRNewswire/ --

protebbe uscire qualcosa
x questo

fine 2015

Regen BioPharma, Inc. (OTCBB: RGBP) announced today the initiation of a collaboration with Dr. Santosh Kesari , Professor and Director of Neuro-oncology at University of California San Diego . The goals of the collaboration is to address questions posed by the FDA regarding Regn BioPharma, Inc.'s planned Phase I/II clinical trial assessing safety with signals of efficacy of the dCellVax gene silenced dendritic cell immunotherapy for treating breast cancer and to modify the existing Investigational New Drug application in order to maximize the probability of clinical trial success . The proposed trial will recruit 10 patients with metastatic breast cancer and will involve 4 monthly injections of the dCellVax gene-silenced dendritic cell therapy. The trial will last one year, with tumor assessment before therapy and at 6 and 12 months.
 
Hanno diluito un po' emettendo un po' di carta per finanziarsi in attesa di news da EfDiEi,
nuove azioni emesse ago/ott 2015:
- common totale 6.349.000 pezzi
- preferred serie A totale 15.700.000 pezzi

Una parte di queste sono state emesse come retribuzione di qualcuno del board...
 
Koos ha anche dato via azioni in cambio di cash...peccato che si sia abbassato le braghe valutandole solo 2 e 4 centesimi!...

"On October 28, 2015 Regen issued 1,666,667 of its shares of Series A Preferred Stock (“Shares”) for cash consideration of $83,333."

"On November 20, 2015 Regen issued 2,200,000 of its shares of Series A Preferred Stock (“Shares”) for cash consideration of $55,000."
 
Regen BioPharma Inc. Attracts Top Researchers to Scientific Advisory Board

SAN DIEGO, December 1, 2015 /PRNewswire/ --

Dr. Harry Lander, President of Regen, expands his role to include serving as Chief Science Officer and recruits five distinguished scientists to join advisory team

Regen BioPharma, Inc., (OTCBB: RGBP) and (PINK: RGBP) today announced that Harry Lander, PhD, currently President of Regen Biopharma, Inc., would also serve as Chief Scientific Officer of the company. Regen also announced that five top researchers have agreed to serve on the company's scientific advisory board. Those researchers are Francesco Marincola, M.D., Ralph Nachman, M.D., Stefano Bertuzzi, Ph.D., Helen Sabzevari, Ph.D. and Lorraine Gudas, Ph.D.

Dr. Lander received a Bachelor of Science degree in biochemistry and a Bachelor of Arts degree in chemistry from State University at Stony Brook in 1987, a doctorate in Biochemistry from Cornell University Graduate School of Medical Sciences in 1992 and an MBA in finance from the New York University Stern School of Business in 2001. Dr. Lander has strong experience as both a researcher and administrator, having served in these positions at Cornell University as well as the Sidra Medical and Research Center in Qatar.

The Regen BioPharma, Inc. scientific advisory board, now numbering 16, will work closely with Dr. Lander and the rest of his management team to advance the firm's small molecule and immuno-oncological therapeutics.

Francesco Marincola, M.D., one of the most recognized tumor immunologists in the world, serves as Chief Research Officer at Sidra Medical and Research Center.

Ralph Nachman, M.D., a renowned hematologist, is a member of the Institute of Medicine and University Professor and former Chairman of Medicine at NY Presbyterian/Weill Cornell Medical Center.

Stefano Bertuzzi, Ph.D., is Executive Director at American Society for Cell Biology and was a senior scientific executive at the National Institutes of Health where he served as Director of Policy and Planning for the Mental Health Institute.

Helen Sabzevari, Ph.D., one of the key leaders in the world in developing immunotherapies, was head of immuno-oncology, global research and early development at MerckSerono.

Lorraine Gudas, Ph.D., is one of the top experts in the world on nuclear receptors and is extremely familiar with the NR2F family of orphan receptors. She is a professor and chairman of the Department of Pharmacology at Weill Cornell Medical College.

"We're putting together a life science dream team," said company Chairman & CEO David Koos. "This is the high-level team we want to shepherd our stem cell and immuno-oncology therapeutics, as well as our novel cancer stem cell therapeutic targets, through development and trials and, ultimately, to the people who need them."

Lander assumes the position of Chief Scientific Officer from Dr. Thomas Ichim, co-founder of Regen BioPharma Inc., who elected to transition to the role of Senior Research Consultant after he and David Koos recruited Dr. Lander as President.

"As the pipeline of the company matures, we need to ensure that we have the right scientific advisors supporting us," said Lander. "Tom is an incredibly creative scientist, and retaining him as our senior research consultant allows us to maintain continuity in our programs and continue to benefit from his remarkable energy and creativity."

About Regen BioPharma, Inc.

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCBB: RGBP) and (OTC PINK: RGBP). The Company seeks to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. The Company is focused on rapidly advancing these technologies through pre-clinical and Phase I/ II clinical trials. Currently the Company is centering on gene silencing therapy, telomeres and small molecule therapies for treating cancers, along with developing stem cell treatments for aplastic anemia.

Disclaimer: This news release may contain forward-looking statements. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks.

Contact Information

Regen BioPharma Inc.
David R. Koos, PhD
Chairman & Chief Executive Officer
+1-619-702-1404
David.koos@regenbiopharma.com
 
....e avanti Savoia...:D altre bocche da sfamare :eek::eek::eek::o


...pero' ragazzi, che razza di squadrone che hanno messo su....:bow::bow::bow:

ooohhh--issa---oooohhh--.issa
 
bemberege ha scritto:
a Regen piace ballare....sono sempre dentro convinto...a livello grafico mi piace molto la tenuta sopra 0,10 ma non ci deve andare sotto...se le cose girano nel verso giusto un altro allungo verso zona 0,38 ci dovrebbe stare mese dicembre gennaio..questa e' la mia speranza....
Clicca per espandere...

vediamo se ci prendo anche questa volta,,,,,,,,,,,,,
 
devi dirmi quando torna a 0,10 che carico il Camion ;-)
 
rgbp
mi sembra strano come a poche settimane dal responso fda sia tutto fermo (volumi)
 
Devi accedere o registrarti per poter rispondere.
Indietro